In this issue:
First line axicabtagene ciloleucel in high-risk LBCL
Ibrutinib + rituximab for indolent MCL
Addition of 4 doses of rituximab to standard induction in B-precursor ALL
Obinutuzumab + lenalidomide in previously untreated FL
Tisagenlecleucel in primary CNS lymphoma
≥3 lines of systemic therapy in R/R FL
Brentuximab vedotin + lenalidomide in R/R DLBCL
PET–driven strategy in advanced Hodgkin lymphoma
Venetoclax delays time to deterioration of QoL in unfit patients with AML
Chidamide + prednisone, etoposide, and thalidomide for untreated AITL
Please login below to download this issue (PDF)